Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 226 to 250 of 323

Guidance and quality standards awaiting development
Title	Type
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Ruxolitinib for treating moderate atopic dermatitis [ID6602]	Technology appraisal guidance
Sabizabulin for treating COVID 19 [TSID11814]	Technology appraisal guidance
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]	Technology appraisal guidance
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]	Technology appraisal guidance
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal	Quality standard
Safeguarding adults in care homes	Quality standard
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Satralizumab for treating thyroid eye disease [ID6648]	Technology appraisal guidance
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]	Technology appraisal guidance
Secondary care management of malignant hypertension	Quality standard
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]	Technology appraisal guidance
Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]	Technology appraisal guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]	Highly specialised technology
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance

Results per page

10
25
50
All